Advertisement
News
Advertisement

LED Medical Diagnostics Announces Investor Relations Services and Warrant Extension

Thu, 06/21/2012 - 12:45pm
The Associated Press

(http://www.VELscope.com)

LED Medical Diagnostics Inc. (TSX VENTURE: LMD) ("LED" or the

"Company") today announced, subject to TSX Venture Exchange approval,

it has entered into an agreement with TradeMark Equity Marketing Inc.

("TEM") of Calgary for the provision of investor relations services.

These services, which will be provided on behalf of TEM by its

principal, Mark Komonoski, are intended to increase communication and

awareness of LED and its activities with the financial community.

Under the agreement, the Company will pay $6,000 per month and will

grant 300,000 stock options (pricing to be determined) to TEM which

will vest over the next three years. Mark Komonoski owns 80,000 common

shares of the Company and may from time to time acquire additional

common shares.

"We are pleased Mark will be joining our team during our rapid growth

phase, bringing with him over 24 years of public market development

experience," commented Peter Whitehead, CEO and founder of LED.

LED also announces, subject to TSX Venture Exchange approval, it has

agreed to extend the term of warrants to acquire 1,430,000 common

shares of the Company that are scheduled to expire on July 9, 2012.

The extension is for an additional 6 months to January 9, 2013. The

warrants were originally issued on July 9, 2010 in connection with a

private placement of units and have an exercise price of $0.65 per

common share.

About LED Medical Diagnostics Inc.

Founded in 2003, LED Medical Diagnostics Inc. (TSX VENTURE: LMD) is a

fast-growing public company offering effective early-stage oral cancer

detection technologies in 23 countries worldwide. The Company makes

the VELscope Vx, the most powerful tool for detecting early stage oral

cancer approved by the FDA, Health Canada and European regulators.

www.VELscope.com(http://www.VELscope.com).

About the VELscope Vx

The VELscope Vx is the most powerful FDA-approved tool used to screen

for oral cancer. It saves lives helping detect early stage oral cancer

and pre-cancer and other abnormalities in the mouth such as viral,

fungal and bacterial infections. The VELscope Vx is exclusively

distributed worldwide through a partnership with Henry Schein, the

world's largest dental distribution company. For more information,

please call +1 (604) 434-4614, or visit

www.VELscope.com(http://www.VELscope.com).

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading